WO2022110958A1 - 含有ras/raf蛋白干扰基团的hdac抑制剂及其制备方法 - Google Patents

含有ras/raf蛋白干扰基团的hdac抑制剂及其制备方法 Download PDF

Info

Publication number
WO2022110958A1
WO2022110958A1 PCT/CN2021/116466 CN2021116466W WO2022110958A1 WO 2022110958 A1 WO2022110958 A1 WO 2022110958A1 CN 2021116466 W CN2021116466 W CN 2021116466W WO 2022110958 A1 WO2022110958 A1 WO 2022110958A1
Authority
WO
WIPO (PCT)
Prior art keywords
hdac inhibitor
compound
ras
equivalents
dcm
Prior art date
Application number
PCT/CN2021/116466
Other languages
English (en)
French (fr)
Inventor
苟少华
夏升进
刘执坤
Original Assignee
东南大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 东南大学 filed Critical 东南大学
Publication of WO2022110958A1 publication Critical patent/WO2022110958A1/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
    • C07C201/06—Preparation of nitro compounds
    • C07C201/12—Preparation of nitro compounds by reactions not involving the formation of nitro groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
    • C07C205/35—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C205/36—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
    • C07C205/37—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/44—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/02—Preparation of sulfones; Preparation of sulfoxides by formation of sulfone or sulfoxide groups by oxidation of sulfides, or by formation of sulfone groups by oxidation of sulfoxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/18—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/14—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the invention specifically relates to the use of 2,4,6-trimethoxyphenyl-4-methoxy-3-aminobenzyl sulfone structural unit targeting RAS/RAF as a cap group to deacetylate histones
  • the hydroxamic acid or benzamide structural unit targeted by Histone deacetylases (HDAC) is a zinc ion binding group, which is connected by a linear group to obtain a class of HDAC inhibitors containing RAS/RAF protein interfering groups.
  • HDAC Histone deacetylases
  • the invention belongs to the preparation method of such compounds in medicinal chemistry and their application field in the preparation of anti-tumor drugs.
  • RAS proteins and related proteins play key roles in numerous cellular regulatory processes, such as cell proliferation and differentiation, intracellular-cytosolic transport, intracellular oxidase production, cytoskeleton regulation and transmembrane transmission of extracellular information.
  • RAS acts as a molecular switch regulating GDP/GTP conversion with the help of extracellular signals, leading to the activation of several downstream cascades including the RAF-MEK-ERK pathway.
  • RAS utilizes its intrinsic GTPase function to switch from an active GTP-binding signaling state to an inactive GTP-binding signaling state.
  • RAS plays an important role in the occurrence and development of human cancers and is an important target for cancer treatment.
  • HDACs are a class of key enzymes that catalyze lysine deacetylation. Studies have shown that it is closely related to biological processes such as gene transcription, cell proliferation, angiogenesis, migration, differentiation, and metastasis, and is overexpressed in various tumor cells such as rectal cancer, gastric cancer, liver cancer, breast cancer, and lung cancer. Therefore, HDAC has become an important target in the design of antitumor drugs.
  • HDACs there are 18 known HDACs, which can be subdivided into four classes according to their sequence homology: class I HDACs, including HDAC1, 2, 3, and 8; class II HDACs, including class IIa HDACs 4, 5, 7, and 8.
  • HDAC inhibitor pharmacophore can be divided into three parts: (1) cap group, used to recognize HDAC active pocket; (2) zinc ion binding group, generally divided into benzamide and hydroxamic acid , which is used to chelate the zinc ion at the bottom of the catalytic pocket of HDAC; (3) the linking group, which is used to link the zinc ion binding group and the capping group.
  • HDAC inhibitors have been marketed for cancer treatment, such as Vorinostat (SAHA), Belinostat (pxd-101), Panobinostat (LBH589), and Tacedinaline (CI994).
  • SAHA Vorinostat
  • pxd-101 Belinostat
  • LH589 Panobinostat
  • Tacedinaline CI994
  • the purpose of the present invention is to use the 2,4,6-trimethoxyphenyl-4-methoxy-3-aminobenzyl sulfone structural unit reported in the literature with RAS/RAF as the target as the cap group
  • the benzamide or hydroxamic acid structural unit with HDAC as the target is a zinc ion binding group, and is connected by a linear group to obtain a class of HDAC inhibitors containing RAS/RAF protein interfering groups; the present invention also discloses Methods for the preparation of such compounds.
  • An HDAC inhibitor containing a RAS/RAF protein interfering group of the present invention is based on a known 2,4,6-trimethoxyphenyl-4-methoxy-targeted RAS/RAF target.
  • -3-Aminobenzyl sulfone (9) is a cap group, and its structure is shown in formula 1,
  • a benzamide or hydroxamic acid structural unit is introduced into its structure through a linking group to obtain a compound whose structure is shown in formula 2, namely an HDAC inhibitor, which is divided into the following representative I-A, I-B, I-C, I-D 4 kinds of compounds,
  • n 1-5.
  • TBTU stands for 2-(1H-benzotriazo L-1-yl)-1,1,3,3-tetramethylurea tetrafluoroborate
  • Et3N stands for triethylamine
  • DMF stands for N,N -dimethylformamide.
  • HDAC inhibitor I-B is prepared according to the following reaction formula 3-2:
  • TBTU stands for 2-(1H-benzotriazo L-1-yl)-1,1,3,3-tetramethylurea tetrafluoroborate
  • Et 3 N stands for triethylamine
  • DMF stands for N , N-dimethylformamide.
  • HDAC inhibitor I-C is prepared according to the following reaction formula 3-3:
  • TBTU 2-(1H-benzotriazo L-1-yl)-1,1,3,3-tetramethylurea tetrafluoroborate
  • Et 3 N represents triethylamine
  • DCM represents diethylamine Chloromethane.
  • HDAC inhibitor I-D was prepared according to the following reaction formula:
  • TBTU represents the condensing agent 2-(1H-benzotriazo L-1-yl)-1,1,3,3-tetramethylurea tetrafluoroborate
  • Et 3 N represents triethylamine
  • DCM stands for dichloromethane.
  • MeOH represents methanol
  • EtOH represents ethanol
  • Et 3 N triethylamine
  • DMF represents N,N-dimethylformamide
  • DCM represents dichloromethane
  • compounds 19 and 34 had the strongest cytotoxic activity against non-small cell lung cancer H1975 cells.
  • the structure-activity relationship indicated that the anticancer activity of the compounds obtained with a longer carbon chain linking group was weaker than that of the compounds obtained with a shorter carbon chain linking group.
  • compounds 19-21 and 34-36 with hydroxamic acid as the zinc ion-binding group had stronger antiproliferative activities than compounds 16-18 and 31-33 with benzamide as the zinc ion-binding group. This may be due to the higher affinity of the structural molecule of hydroxamic acid, which is easier to bind to zinc ions, resulting in higher cytotoxicity.
  • the hydroxamic acid or benzamide structural unit with histone deacetylase (Histone deacetylases, HDAC) as the target is a zinc ion binding group, and is connected by a linear group to obtain a kind of protein interference containing RAS/RAF.
  • HDAC histone deacetylases
  • compound 12 was obtained using oxalyl chloride (2 mL), DCM (20 mL), monomethyl adipate (6.3 mmol), Et3N (1048.5 ⁇ L) and compound 9 (5.7 mmol). Yellow solid, 85.4% yield.
  • compound 11 was used instead of compound 10 to react to obtain a pale yellow solid with a yield of 91.0%.
  • compound 12 was used instead of compound 10 to react to obtain a light yellow solid with a yield of 90.5%.
  • compound 23 was used instead of compound 22 to react to obtain compound 26. Yellow solid, 82.1% yield.
  • compound 26 was used instead of compound 25 to react to obtain a pale yellow solid with a yield of 87.6%.
  • compound 27 was used instead of compound 25 to react to obtain a pale yellow solid with a yield of 88.4%.
  • compound 14 was used instead of compound 13 to react to obtain a light yellow solid with a yield of 38.4%.
  • compound 15 was used instead of compound 13 to react to obtain a pale yellow solid with a yield of 37.6%.
  • compound 15 was used instead of compound 13 to react to obtain a yellow solid with a yield of 63.6%.
  • compound 29 was used instead of compound 28 to react to obtain a pale yellow solid with a yield of 38.4%.
  • compound 30 was used instead of compound 28 to react to obtain a pale yellow solid with a yield of 39.3%.
  • compound 29 was used instead of compound 28 to react to obtain a pale yellow solid with a yield of 51.2%.
  • compound 30 was used instead of compound 28 to react to obtain a pale yellow solid with a yield of 50.2%.
  • Experimental method count the cells in the logarithmic growth phase and inoculate them in a 96-well culture plate, with about 8000-10000 cells per well. The cells were cultured overnight and administered after the cells adhered to the wall. The administration group and the control group were set up respectively.
  • the target compound to be tested is prepared into a stock solution with DMSO solution, and diluted to a series of concentrations with cell culture medium before use, wherein the final concentration of DMSO does not exceed 4 ⁇ (similar to the following experiments). Three replicate wells were set for each concentration.
  • the target compounds were tested for their antiproliferative activities on non-small cell lung cancer cells A549 and H1975, gastric cancer cells SGC-7901, liver cancer cells HepG2, breast cancer cells MCF-7 and epidermal cancer cells A431 and their antiproliferative activities on human normal hepatocytes LO2 and umbilical veins Toxicity of endothelial HUVECs, parent compound 9 and HDAC inhibitor SAHA were used as positive controls. The inhibitory effect of the compound on tumor cell growth at different concentrations was observed, and the inhibition rate and its IC50 value were calculated to evaluate the cytotoxic activity of the drug. The results are shown in Table 2.
  • target compounds 19 and 34 were tested on pancreatic cancer cells PANC-1, colon cancer cells HT29, chronic myeloid leukemia cancer cells K562, and human myelomonocytic leukemia cells MV4-11, parent compound 9 and HDAC inhibition
  • the agent SAHA was used as a positive control.
  • the inhibition of the growth of tumor cells by the compounds at different concentrations was observed, and the inhibition rate and its IC 50 value were calculated to evaluate the cytotoxic activity of the drug. The results are shown in Table 3.
  • HDAC1 HDAC2, HDAC3, HDAC4, HDAC6, HDAC8
  • SAHA HDAC inhibitor
  • the supernatant was divided into two groups, one was the IP group, RAS antibody was added to the supernatant, and the supernatant was slowly shaken at 4°C overnight. Add fully resuspended protein G agarose and shake slowly at 4°C for 4h. Centrifuge at 2500 rpm for 5 min, carefully remove the supernatant, and wash the pellet 5 times with PBS. After washing, remove the supernatant, add 1xSDS-PAGE electrophoresis loading buffer to resuspend, and after mixing, take a water bath at 95°C for 10min as a sample protein, and then detect it by immunoblotting. The other group was used as the input group.
  • 1xSDS-PAGE electrophoresis loading buffer was directly added to the supernatant to resuspend, and after mixing, the sample protein was used in a water bath at 95°C for 10 minutes, and then detected by the experimental method of immunoblotting.
  • the separating gel and stacking gel After the gel is formed, add an appropriate amount of sample protein to the sample well, add pre-stained protein marker to the well next to the sample, and add 1x SDS loading buffer to the well without sample supernatant. The liquid keeps the glue surface balanced. Turn on the power, set the voltage to 60V, and start electrophoresis. When the protein sample enters the separation gel, the voltage can be increased to 120V. After the electrophoresis was completed, the PVDF membrane was transferred, and the current flow was set to 1.1A, the voltage was 25V, and the time was 30min for semi-dry transfer. After the transfer, the PVDF membrane was taken out and labeled, and washed three times with TBST solution for 10 min each time.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明是一种含有RAS/RAF蛋白干扰基团的HDAC抑制剂及其制备方法，所述的一类HDAC抑制剂，是基于已知的以RAS/RAF为靶点的2,4,6-三甲氧基苯基-4-甲氧基-3-氨基苄基砜为帽基基团，以组蛋白去乙酰化酶(Histone deacetylases,HDAC)为靶点的羟肟酸或苯甲酰胺结构单元为锌离子结合基团，通过线性基团连接，得到一类含有RAS/RAF蛋白干扰基团的HDAC抑制剂，以期获得高效低毒的抗肿瘤药物；本发明还披露了这类化合物的制备方法以及它们在制备抗肿瘤药物方面的应用。

Description

含有RAS/RAF蛋白干扰基团的HDAC抑制剂及其制备方法 技术领域
本发明具体涉及利用以RAS/RAF为靶点的2,4,6-三甲氧基苯基-4-甲氧基-3-氨基苄基砜结构单元为帽基基团，以组蛋白去乙酰化酶(Histone deacetylases,HDAC)为靶点的羟肟酸或苯甲酰胺结构单元为锌离子结合基团，通过线性基团连接，得到一类含有RAS/RAF蛋白干扰基团的HDAC抑制剂，以期获得高效低毒的抗肿瘤药物；本发明属于药物化学中这类化合物的制备方法以及它们在制备抗肿瘤药物方面的应用领域。
背景技术
作为鸟嘌呤核苷酸结合蛋白的成员，RAS蛋白及相关蛋白在众多的细胞调节过程中起着关键作用，如细胞增殖与分化、胞内胞液间运输、胞内氧化酶的产生、细胞骨架的调控和胞外信息的跨膜传递等。RAS在细胞外信号的帮助下，作为调节GDP/GTP转化的分子开关，可导致包括RAF-MEK-ERK通路在内的几个下游级联的激活。在细胞外刺激时，RAS利用其固有的GTPase功能，从活跃的GTP结合信号状态切换到不活跃的GTP结合信号状态。由于RAS家族的三种亚型(HRAS、NRAS和KRAS)经常发生突变，而RAS基因的突变会降低GTPase的活性或增加GAPs的不敏感性，其反过来会激活RAS蛋白，从而导致细胞生长失控诱发癌变。这些事实表明，RAS在人类癌症的发生、发展过程中发挥了重要的作用，是治疗癌症的一个重要靶点。
HDAC是一类催化赖氨酸去乙酰化的关键酶。研究显示它与基因转录、细胞增殖、血管生成、迁移、分化、转移等生物学过程密切相关，在直肠癌、胃癌、肝癌、乳腺癌和肺癌等多种肿瘤细胞中都有过表达现象。因此，HDAC已成为抗肿瘤药物设计中的重要靶点。目前，已知的HDAC有18种，根据其序列同源性可细分为四类：I类HDAC，包含HDAC1、2、3和8；II类HDAC，包含IIa类的HDAC4、5、7和9与IIb类的HDAC6和10；III类HDAC，包含sir2相关酶(sirtuins)；IV类HDAC，包含HDAC11。通常，HDAC抑制剂药效团可分为三部分：(1)帽基基团，用于识别HDAC活性口袋；(2)锌离子结合基团，一般分为苯甲酰胺和羟肟酸两种，用于螯合HDAC催化口袋底部的锌离子；(3)连接基团，用于连接锌离子结合基团与帽基基团。迄今为止，已有几种HDAC抑制剂上市用于癌症治疗，如Vorinostat(SAHA)、Belinostat(pxd-101)、Panobinostat(LBH589)和Tacedinaline(CI994)等。不过、已上市的HDAC抑制剂对实体瘤的治疗效果不甚理想，而且产生多种副作用，限制了它们在临床上的应用范围。因此，研发新型的HDAC抑制剂作为抗肿瘤药物是十分有益的。
发明内容
技术问题：本发明的目的是利用文献报道的以RAS/RAF为靶点的2,4,6-三甲氧基苯基-4-甲氧基-3-氨基苄基砜结构单元为帽基基团，以HDAC为靶点的苯甲酰胺或羟肟酸结构单元为锌离子结合基团，通过线性基团连接，得到一类含有RAS/RAF蛋白干扰基团的HDAC抑制剂；本发明还披露这类化合物的制备方法。
技术方案：本发明的一种含有RAS/RAF蛋白干扰基团的HDAC抑制剂是基于已知的以RAS/RAF为靶点的2,4,6-三甲氧基苯基-4-甲氧基-3-氨基苄基砜(9)为帽基基团，其结构如式1所示，
Figure PCTCN2021116466-appb-000001
通过连接基团在其结构引入苯甲酰胺或羟肟酸结构单元，得到结构如式2所示的化合物即HDAC抑制剂，分为以下具有代表性的I-A、I-B、I-C、I-D 4种化合物，
Figure PCTCN2021116466-appb-000002
式2中，n＝1-5。
本发明的含有RAS/RAF蛋白干扰基团的HDAC抑制剂的制备方法，其中，HDAC抑制剂I-A按照以下反应式3-1进行制备：
Figure PCTCN2021116466-appb-000003
其中，TBTU代表2-(1H-苯并三偶氮L-1-基)-1,1,3,3-四甲基脲四氟硼酸酯，Et3N代表三乙胺，DMF代表N,N-二甲基甲酰胺。
合成HDAC抑制剂I-A具体采用如下步骤：
将化合物13、14或15与1.0-1.5当量TBTU溶于无水DMF中，在室温下搅拌5-10min，加入1.0-1.5当量的Et3N，再加入1.0-2.0当量的邻苯二胺，在氮气保护下，反应液于25-35℃下搅拌2-4h，然后减压除去溶剂，浓缩液经硅胶柱层析分离，洗脱液为DCM与CH3OH混合溶剂，分别对应得到化合物16、17或18淡黄色固体产物。
HDAC抑制剂I-B按照以下反应式3-2进行制备：
Figure PCTCN2021116466-appb-000004
其中，TBTU代表2-(1H-苯并三偶氮L-1-基)-1,1,3,3-四甲基脲四氟硼酸酯，Et 3N代表三乙胺，DMF代表N,N-二甲基甲酰胺。
合成HDAC抑制剂I-B具体采用如下步骤：
将化合物13、14或15与1.0-1.5当量TBTU溶于无水DMF中，在室温下搅拌5-10min，加入1.0-1.5当量的Et 3N，再加入1.0-2.0当量的盐酸羟胺，在氮气保护下，反应液于25-35℃下搅拌2-4h，然后减压除去溶剂，浓缩液经硅胶柱层析分离，洗脱液为DCM与CH 3OH混合溶剂，分别对应 得到化合物19、20或21淡黄色固体产物。
HDAC抑制剂I-C按照以下反应式3-3进行制备：
Figure PCTCN2021116466-appb-000005
其中，TBTU代表2-(1H-苯并三偶氮L-1-基)-1,1,3,3-四甲基脲四氟硼酸酯，Et 3N代表三乙胺，DCM代表二氯甲烷。
合成HDAC抑制剂I-C具体采用如下步骤：
将化合物28、29或30与1.0-1.5当量HATU溶于无水DCM中，在室温下搅拌5-10min，加入1.0-1.5当量的Et 3N，再加入1.0-2.0当量的邻苯二胺，在氮气保护下，反应液于25-35℃下搅拌2-4h，然后减压除去溶剂，浓缩液经硅胶柱层析分离，洗脱液为DCM与CH 3OH混合溶剂，得到31、32或33淡黄色固体产物。
HDAC抑制剂I-D按照以下反应式进行制备：
Figure PCTCN2021116466-appb-000006
其中，TBTU代表缩合剂2-(1H-苯并三偶氮L-1-基)-1,1,3,3-四甲基脲四氟硼酸酯，Et 3N代表三乙胺，DCM代表二氯甲烷。
合成HDAC抑制剂I-D具体采用如下步骤：
将化合物28、29或30与1.0-1.5当量TBTU溶于无水DCM中，在室温下搅拌5-10min，加入1.0-1.5当量的Et 3N，再加入1.0-2.0当量的盐酸羟胺，在氮气保护下，反应液于25-35℃下搅拌2-4h，然后减压除去溶剂，浓缩液经硅胶柱层析分离，洗脱液为DCM与CH 3OH混合溶剂，得到34、35或36淡黄色固体产物。
进一步的，式1中化合物9及其衍生物13、14、15、28、29和30的制备按式4所示的反应式进行。
Figure PCTCN2021116466-appb-000007
式4中，MeOH代表甲醇，EtOH代表乙醇，Et 3N代表三乙胺，DMF代表N,N-二甲基甲酰胺，DCM代表二氯甲烷，THF代表四氢呋喃；除特别指明外，n＝1-5。
化合物9及其衍生物13、14、15、28、29和30采用如下方法制备：
1)化合物2-9根据文献方法(J.Med.Chem.2020,63,186–204)合成；
2)化合物10、11或12的合成：将丁二酸单乙酯、戊二酸单甲酯或己二酸单甲酯溶解于DCM中，在0℃下加入草酰氯，室温搅拌过夜。减压蒸馏除去溶剂，再用DCM溶解后，加入化合物9，室温搅拌15min后逐滴滴加Et 3N，继续搅拌2h。反应完成后，用DCM萃取溶液，有机相用饱和食盐水洗涤三次，再用无水硫酸钠干燥后浓缩，得到黄色固体10、11或12。
3)化合物13、14或15的合成：将化合物10、11或12溶解于EtOH:H 2O(2:1)溶液中,在室温下加入LiOH·H 2O，然后搅拌过夜。反应完成后，减压蒸馏除去溶剂，得到淡黄色固体，用少量水洗，过滤得到淡黄色固体13、14或15。
4)化合物25、26或27的合成：将化合物9溶解于DMF中，室温下加入化合物溴乙酸乙酯(22)、溴丙酸乙酯(23)或溴己酸乙酯(24)，再加入K 2CO 3和KI，在氮气的保护下，反应混合溶液于70℃下搅拌3h。反应完成后，用DCM萃取溶液，有机相用饱和食盐水洗涤三次，再用无水硫酸钠干燥后，减压蒸馏除去溶剂，得到的固体以PE(石油醚)：EA(乙酸乙酯)：DCM(二氯甲烷)(10:1:1-60:1:1)为洗脱剂，经硅胶柱层析法进一步分离纯化，得到黄色固体25、26或27。
5)化合物28、29或30的合成：将化合物25、26或27溶解于THF:H 2O(2:1)混合溶液中，于室温下加入LiOH·H 2O，然后搅拌24h。反应完成后，减压蒸馏除去溶剂后，得到淡黄色固体，用少量水洗，过滤得到淡黄色固体28、29或30。
本发明所述的一些代表性化合物的结构如表1所示，但这些代表性化合物并不是限制本发明的范围。
表1.代表性化合物的结构
Figure PCTCN2021116466-appb-000008
有益效果：采用MTT方法首先测定了代表性化合物对六种癌细胞A549、H1975、MCF-7、SGC7901、HepG2、A431的抗癌活性，具体结果见表2。目标化合物16-21和31-36均具有抗癌活性。值得注意的是化合物19和34对所测癌细胞表现出强的抗癌活性，其中化合物19的IC50值在0.084-1.68μM之间，化合物34的IC50值在0.045-0.99μM之间，明显高于母体化合物9的活性。与阳性对照SAHA(IC50值介于4.64至7.56μM之间)相比，化合物19和34的抗癌活性也明显更高。在所测试的六种癌细胞中，化合物19和34对非小细胞肺癌H1975细胞的细胞毒活性最强。构效关系表明，采用较长碳链连接基团所得化合物的抗癌活性比采用较短碳链连接基团所得化合物的抗癌活性要弱。此外，以羟肟酸作为锌离子结合基团的化合物19-21和34-36比以苯甲酰胺作为锌离子结合基团的化合物16-18和31-33具有更强的抗增殖活性。这可能是由于羟肟酸的结构分子具有较高的亲和力，更容易与锌离子结合，导致更高的细胞毒性。此外，还测定了这些化合物对人正常肝细胞LO2和脐静脉内皮细胞HUVEC的毒性。虽然化合物19和34对所测的任一癌细胞的毒性都高于阳性对照药物SAHA对癌细胞的毒性，但是它们对正常细胞的毒性低于SAHA。这表明所得的HDAC抑制剂在提高抗肿瘤活性的同时，还降低了对正常细胞的毒性。
我们还测试了化合物19和34对四种癌细胞PANC-1、HT29、K562、MV4-11的抗癌活性，母体化合物9和HDAC抑制剂SAHA为阳性对照，结果见表3。化合物34对所测癌的细胞表现出很强的抗癌活性，其IC50值在0.022-0.80μM之间，明显高于母体化合物9和药物SAHA的活性，也优于 化合物19。
根据上述结果，我们测试了化合物19和34对HDAC的活性，结果见表4。化合物19和34对HDAC 1、2、3、4、6和8均具有很好的抑制作用，其中对HDAC1、2和3的IC50值在8-20nM区域内，而对HDAC 4、6和8的IC50值则在60-90nM区域内。化合物19和34对HDAC1、2和3的抑制作用明显高于HDAC4和6，这表明它们可选择性地的抑制I类HDAC。化合物19和34对HDAC3表现出了显著的抑制效果，其IC50值分别为9.61nM和8.97nM。需要指出的是，SAHA对HDAC8抑制活性达到微摩尔级别，几乎没有抑制作用，而化合物19和34对HDAC8仍然具有中等强度的抑制作用，其IC50值分别为89.76nM和88.64nM。此外，化合物19和34对II类HDAC4和6的抑制效果也明显高于SAHA。综上，引入高活性帽基结构基团有助于提高对HDAC的抑制作用。
我们使用免疫共沉淀实验和免疫印迹分析，测试了化合物19和34对RAS和RAF蛋白表达的影响，结果见图1。在input组中，经过19和34处理的细胞，RAS蛋白表达无明显变化，而P-RAF(C-RAFSser338)蛋白的表达却明显下调。在IP组中，经过19和34处理的细胞，RAS蛋白表达仅有轻微的下调，但P-RAF(C-RAFSser338)蛋白的表达则明显下调，且下调效果优于阳性对照化合物9,而SAHA则对RAS和RAF蛋白的表达没有影响。结果表明，RAS和RAF是目标化合物19和34的靶向蛋白，它们可以阻断RAS和RAF蛋白之间的信号转导，从而导致P-RAF蛋白表达下调。
体外抗癌活性和HDAC活性试验以及免疫共沉淀和免疫印迹实验结果表明，本发明所述的目标化合物对一些癌细胞具有显著的抑制作用，可用于制备药物。
附图说明
图1.化合物对RAS-RAF蛋白的作用。
具体实施方式
本发明以组蛋白去乙酰化酶(Histone deacetylases,HDAC)为靶点的羟肟酸或苯甲酰胺结构单元为锌离子结合基团，通过线性基团连接，得到一类含有RAS/RAF蛋白干扰基团的HDAC抑制剂，以期获得高效低毒的抗肿瘤药物；本发明还披露了这类化合物的制备方法以及它们在制备抗肿瘤药物方面的应用。
本发明由下述实施例进一步的说明，但这些说明并不限制本发明。除特别指出外，一些化合物如化合物2-9采用文献方法制备。按本发明方法制备的化合物经核磁氢谱和碳谱及高分辨质谱确定了化合物的分子结构。
(一)、化合物9及其衍生物13、14、15、28、29和30的制备
(1)化合物2的制备
将化合物1(3.0g，18.0mmol)溶解于DMF(30.0mL)中，加入CH3I(3.8g，26.7mmol)和无水K2CO3(6.2g，45.0mmol)，室温搅拌过夜。通过TLC监测反应。反应完成后，减压蒸馏除去溶剂，得到粗产物。用DCM溶解粗产物，并用饱和食盐水溶液(100mL)洗涤三次。有机层用无水硫酸钠干燥后真空浓缩，得到白色固体。产率91.5％。
1H NMR(600MHz,CDCl3)δ9.95(s,1H),8.36(d,J＝2.1Hz,1H),8.10(dd,J＝8.7,2.1Hz,1H),7.25(d,J＝8.7Hz,1H),4.07(s,3H).
(2)化合物3的制备
将化合物2(1.01g，5.58mmol)溶解于20mL MeOH中，在0℃下逐渐添加NaBH4(0.27g，7.25mmol)，并在相同温度下搅拌20分钟。使用TLC监测反应进程。反应完成后在0℃下滴加1M HCl溶液，减压蒸馏除去溶剂，获得白色固体粗产物。然后加入DCM(300mL)溶解粗产物，并用饱和食盐水溶液(100mL)洗涤三次。有机层用无水硫酸钠干燥后真空浓缩，得到白色固体。产率：100％。
1H NMR(600MHz,CDCl3)δ7.85(d,J＝2.1Hz,1H),7.54(dd,J＝8.6,2.1Hz,1H),7.08(d,J＝8.6Hz,1H),4.68(s,2H),3.96(s,3H),1.99(s,1H).
(3)化合物4的制备
将化合物3(600.0mg，3.28mmol)溶解于20mL DCM中,在0℃下逐渐添加PBr3(1.32g，4.92mmol)，并在相同温度下搅拌3h，用TLC监测反应过程。反应完成后，在0℃下滴加1M NaHCO3溶液反应。将得到的固体产物用DCM溶解，用饱和食盐水溶液(100mL)洗涤三次，有机层用无水硫酸钠干燥后，真空浓缩，得到白色固体。产率99.3％。
1H NMR(600MHz,CDCl3)δ7.90(d,J＝2.3Hz,1H),7.58(dd,J＝8.6,2.3Hz,1H), 7.07(d,J＝8.7Hz,1H),4.47(s,2H),3.97(s,3H).
(4)化合物5的制备
将化合物4(1g,4mmol)溶解于20mL MeOH中,在0℃下添加TGA(467.92mg,5mmol)，和NaOH(337.79mg,8.53mmol)，反应混合物在室温下搅拌3h，通过TLC监测反应进程。反应完成后，在0℃下滴加1M HCl溶液，减压蒸馏除去溶剂，获得固体粗产物。用少量水洗，过滤得到淡黄色固体。产率90.1％。
1H NMR(600MHz,DMSO)δ12.64(s,1H),7.83(d,J＝2.2Hz,1H),7.61(dd,J＝8.6,2.3Hz,1H),7.34(d,J＝8.7Hz,1H),3.92(s,3H),3.83(s,2H),3.14(s,2H).
HR-MS(m/z)(ESI):calcd for C10H11NO2S,[M-H]-:256.04；found:256.0498.
(5)化合物6的制备
将化合物5(514.6mg,3.8mmol)溶解于20mL AcOH中，在室温下逐滴添加30％的H2O2溶液(1.322g,38.8mmol)，反应混合物在50℃下搅拌6h，通过TLC监测反应进程。反应完成后减压蒸馏除去溶剂，获得粗产物。以DCM:MeOH(80:1-20:1)为洗脱剂，经硅胶层析法分离纯化，得淡黄色固体。产率71.4％。
1H NMR(600MHz,DMSO)δ7.92(d,J＝2.2Hz,1H),7.68(dd,J＝8.7,2.2Hz,1H),7.43(d,J＝8.8Hz,1H),4.69(s,2H),4.22(s,2H),3.95(s,3H).
HR-MS(m/z)(ESI):calcd for C10H11NO7S,[M-H]-:288.03；found:288.0324.
(6)化合物8的制备
将化合物6(514.6mg,3.8mmol)溶解于30mL甲苯中，依次加入哌啶(412μL,4.2mmol)、苯甲酸(650mg,5.2mmol)、化合物7(1.1g,5.7mmol)，在40℃下搅拌回流过夜，通过TLC监测反应进程。反应完成后，溶液冷却至室温，过滤，得粗产物，用MeOH重结晶，得黄色固体。产率36.3％。
1H NMR(600MHz,DMSO)δ7.88(d,J＝1.9Hz,1H),7.64(dd,J＝8.7,1.9Hz,1H),7.50(d,J＝15.6Hz,1H),7.39(d,J＝8.7Hz,1H),7.09(d,J＝15.6Hz,1H),6.29(s,2H),4.55(s,2H),3.93(s,3H),3.85(s,9H).
(7)化合物9的制备
将化合物8(3.60g,8.6mmol)溶解于20mL EtOH中，依次加入H2O(10mL)，NH4Cl(2.27g,5.2mmol)，Fe粉(2.86g,50.1mmol)，反应混合物在70℃下搅拌6h，通过TLC监测反应进程。在反应完成后，过滤除去固体残渣，获得的滤液减压蒸馏除去溶剂，得粗产物，再用DCM重结晶，得黄色固体。产率91.1％。
1H NMR(600MHz,DMSO)δ7.59(d,J＝15.7Hz,1H),7.09(d,J＝15.7Hz,1H),6.74(d,J＝8.2Hz,1H),6.63(d,J＝2.1Hz,1H),6.49(dd,J＝8.2,2.1Hz,1H),6.29(s,2H),4.77(s,2H),4.21(s,2H),3.85(s,6H),3.84(s,3H),3.74(s,3H).
HR-MS(m/z)(ESI):calcd for C19H23NO6S,[M+H]+:394.13；found:394.1315.
(8)化合物10的制备
将丁二酸单乙酯(919.8mg,6.3mmol)溶解于20mL DCM溶液中，在0℃下加入草酰氯(2mL)，反应混合物在室温下搅拌过夜。减压蒸馏去除溶剂获得无色油状物，用DCM(5mL)溶解后，在0℃下加至含有化合物9(2.25g,5.7mmol)的DCM(15mL)溶液中，搅拌15min后，逐滴加入Et3N(761.7mg,1048.5μL)，再继续搅拌2h，通过TLC监测反应进程。在反应完成后，用DCM(300mL)萃取溶液，有机相用饱和食盐水溶液(100mL)洗涤三次，再用无水硫酸钠干燥后，真空浓缩，得到黄色固体。产率86.2％.
1H NMR(600MHz,CDCl3)δ8.35(s,1H),7.87(s,1H),7.84(d,J＝15.6Hz,1H),7.15(dd,J＝8.3,1.8Hz,1H),7.09(d,J＝15.6Hz,1H),6.87(d,J＝8.4Hz,1H),6.08(s,2H),4.20(s,2H),4.16–4.13(m,2H),3.88(s,3H),3.84(s,3H),3.82(s,6H),2.69(dd,J＝7.8,4.4Hz,4H),1.26(t,J＝7.1Hz,3H).
HR-MS(m/z)(ESI):calcd for C25H31NO9S,[M+H]+:522.17；found:522.1800.
(9)化合物11的制备
按照上述化合物10的合成方法，使用草酰氯(2mL)、DCM(20mL)、戊二酸单甲酯(6.3mmol)、Et3N(1048.5μL)和化合物9(5.7mmol)获得化合物11。黄色固体，产率88.3％.
1H NMR(600MHz,CDCl3)δ8.37(s,1H),7.84(d,J＝15.6Hz,1H),7.72(s,1H),7.15(dd,J＝8.4,2.0Hz,1H),7.09(s,1H),6.87(d,J＝8.4Hz,1H),6.08(s,2H),4.21(s,2H),3.88(s,3H),3.84(s,3H),3.83(s,6H),3.68(s,3H),2.43(dd,J＝13.7,7.0Hz,4H),2.02(p,J＝7.2Hz,2H).
HR-MS(m/z)(ESI):calcd for C25H31NO9S,[M-H]-:520.17；found:520.1772
(10)化合物12的制备
按照上述化合物10的合成方法，使用草酰氯(2mL)、DCM(20mL)、己二酸单甲酯(6.3mmol)、Et3N(1048.5μL)和化合物9(5.7mmol)获得化合物12。黄色固体，产率85.4％.
1H NMR(600MHz,CDCl3)δ8.37(s,1H),7.84(d,J＝15.6Hz,1H),7.70(s,1H),7.15(dd,J＝8.4,1.8Hz,1H),7.11(d,J＝15.6Hz,1H),6.87(d,J＝8.4Hz,1H),6.08(s,2H),4.21(s,2H),3.88(s,3H),3.84(s,3H),3.83(s,6H),3.67(s,3H),2.39–2.34(m,4H),1.71(dd,J＝6.9,4.1Hz,4H).
HR-MS(m/z)(ESI):calcd for C26H33NO9S,[M+H]+:536.20；found:536.2076.
(11)化合物13的制备
将化合物10(1773.1mg,3.4mmol)溶解于EtOH：H2O(2:1,30mL)中,在室温下加入LiOH·H2O(357mg,8.5mmol)，然后室温搅拌过夜，通过TLC监测反应进程。反应完成后，减压蒸馏除去溶剂，获得固体粗产物。用少量水洗，过滤得到淡黄色固体。产率97.0％.
1H NMR(600MHz,DMSO)δ12.14(s,1H),9.16(s,1H),8.03(s,1H),7.59(d,J＝15.6Hz,1H),7.11(d,J＝15.6Hz,1H),7.04–6.99(m,2H),6.29(s,2H),4.34(s,2H),2.63(t,J＝6.6Hz,2H),2.47(d,J＝6.6Hz,2H).
HR-MS(m/z)(ESI):calcd for C23H27NO9S,[M-H]-:492.16；found:492.1654.
(12)化合物14的制备
按照上述化合物13的合成方法，使用化合物11代替化合物10反应，得到淡黄色固体，产率91.0％.
1H NMR(600MHz,DMSO)δ12.09(s,1H),9.09(s,1H),7.97(s,1H),7.59(d,J＝15.6Hz,1H),7.12(d,J＝15.6Hz,1H),7.04(dd,J＝8.5,1.3Hz,1H),7.01(d,J＝8.5Hz,1H),6.29(s,2H),4.35(s,2H),3.85(s,6H),3.84(s,3H),3.82(s,3H),2.40(t,J＝7.3Hz,2H),2.26(t,J＝7.4Hz,2H),1.81–1.74(m,2H).
HR-MS(m/z)(ESI):calcd for C24H29NO9S,[M-H]-:506.18；found:506.1856.
(13)化合物15的制备
按照上述化合物13的合成方法，使用化合物12代替化合物10反应，得到淡黄色固体，产率90.5％.
1H NMR(600MHz,DMSO)δ12.02(s,1H),9.06(s,1H),7.98(s,1H),7.59(d,J＝15.6Hz,1H),7.12(d,J＝15.7Hz,1H),7.04(dd,J＝8.5,1.2Hz,1H),7.01(d,J＝8.5Hz,1H),6.29(s,2H),4.34(s,2H),3.85(s,6H),3.84(s,3H),3.82(s,3H),2.37(t,J＝6.7Hz,2H),2.23(t,J＝7.0Hz,2H),1.58–1.50(m,4H).
HR-MS(m/z)(ESI):calcd for C25H31NO9S,[M+H]+:522.18；found:522.1822.
(14)化合物25的制备
将化合物9(393.4mg,1mmol)溶解于DMF(30mL)中，室温下依次加入化合物22(664.0mg,4mmol)，K2CO3(552.0mg,4mmol)和KI(66.4mg,0.4mmol)，在氮气的保护下，反应混合溶液于70℃下搅拌3h，通过TLC监测反应进程。在反应完成后，用DCM(300mL)萃取溶液，有机相用饱和食盐水溶液(100mL)洗涤三次，再用无水硫酸钠干燥后，减压蒸馏，得到的固体以PE:EA:DCM(10:1:1-60:1:1)为洗脱剂，经硅胶层析法分离纯化，得黄色固体。产率80.0％.
1H NMR(600MHz,CDCl3)δ7.80(d,J＝15.7Hz,1H),7.26(s,1H),7.04(d,J＝15.7Hz,1H),6.73(d,J＝8.1Hz,1H),6.71(dd,J＝8.1,1.9Hz,1H),6.50(d,J＝1.8Hz,1H),6.08(s,2H),4.22(q,J＝7.1Hz,2H),4.16(s,2H),3.86(s,2H),3.85(s,3H),3.84(s,3H),3.82(s,6H),1.28(t,J＝7.1Hz,3H).
HR-MS(m/z)(ESI):calcd for C23H29NO8S,[M+H]+:480.16；found:480.1698.
(15)化合物26的制备
按照上述化合物25的合成方法，用化合物23代替化合物22反应，得到化合物26。黄色固体，产率82.1％.
1H NMR(600MHz,CDCl3)δ7.84(d,J＝15.7Hz,1H),7.06(d,J＝15.7Hz,1H),6.72(d,J＝8.1Hz,1H),6.69(dd,J＝8.1,1.8Hz,1H),6.62(d,J＝1.6Hz,1H),6.09(s,2H),4.17(s,2H),4.16–4.12(m,2H),3.84(s,3H),3.83(s,3H),3.82(s,6H),3.41(t,J＝6.5Hz,2H),2.57(d,J＝6.5Hz,2H),1.26(d,J＝7.1Hz,3H).
HR-MS(m/z)(ESI):calcd for C24H31NO8S,[M+H]+:494.18；found:494.1865.
(16)化合物27的制备
按照上述化合物25的合成方法，用化合物24代替化合物22反应，得到化合物27。黄色固体，产率84.2％.
1H NMR(600MHz,CDCl3)δ7.83(d,J＝15.7Hz,1H),7.05(d,J＝15.7Hz,1H),6.70(d,J＝8.1Hz,1H),6.65(dd,J＝8.1,2.0Hz,1H),6.58(d,J＝1.9Hz,1H),6.08(s,2H),4.22(s,1H),4.16(s,2H),4.14–4.10(m,2H),3.84(s,3H),3.82(s,3H),3.81(s,6H),3.11(t,J＝6.9Hz,2H),2.36(t,J＝7.3Hz,2H),1.91(dd,J＝14.3,7.1Hz,2H),1.24(d,J＝7.1Hz,3H).
HR-MS(m/z)(ESI):calcd for C27H37NO8S,[M+H]+:536.23；found:536.2331
(17)化合物28的制备
将化合物25(719.1mg,1.5mmol)溶解于THF:H2O(2:1；30mL)混合溶剂中，于室温下加入LiOH·H2O(126mg,3mmol)，然后搅拌24h，通过TLC监测反应进程。在反应完成后，溶液减压蒸馏除去溶剂，获得淡黄色粗产物。粗产物用少量水洗后，过滤得到淡黄色固体，产率89.4％.
1H NMR(600MHz,DMSO)δ7.55(d,J＝15.7Hz,1H),7.11(d,J＝15.7Hz,1H),6.80(d,J＝8.2Hz,1H),6.58(dd,J＝8.1,1.9Hz,1H),6.42(d,J＝2.0Hz,1H),6.29(s,2H),5.75(s,1H),4.26(s,2H),3.85(s,6H),3.84(s,3H),3.79(s,3H),3.72(s,2H).
HR-MS(m/z)(ESI):calcd for C21H25NO8S,[2M+H]+:903.28；found:903.2828
(18)化合物29的制备
按照上述化合物28的合成方法，使用化合物26代替化合物25反应，得到淡黄色固体，产率87.6％.
1H NMR(600MHz,DMSO)δ7.55(d,J＝15.7Hz,1H),7.11(d,J＝15.7Hz,1H),6.80(d,J＝8.2Hz,1H),6.58(dd,J＝8.1,1.9Hz,1H),6.42(d,J＝2.0Hz,1H),6.29(s,2H),5.75(s,1H),4.26(s,2H),3.85(s,6H),3.84(s,3H),3.79(s,3H),3.72(s,2H).
HR-MS(m/z)(ESI):caled for C22H27NO8S,[M+H]+:466.16；found:466.1568
(19)化合物30的制备
按照上述化合物28的合成方法，使用化合物27代替化合物25反应，得到淡黄色固体，产率88.4％。
1H NMR(600MHz,DMSO)δ12.01(s,1H),7.53(d,J＝15.7Hz,1H),7.11(d,J＝15.7Hz,1H),6.75(d,J＝8.2Hz,1H),6.52(dd,J＝8.1,1.9Hz,1H),6.47(d,J＝1.9Hz,1H),6.29(s,2H),4.73(s,1H),4.28(s,2H),3.84(s,9H),3.76(s,3H),2.91(t,J＝6.8Hz,2H),2.17(t,J＝7.4Hz,2H),1.50–1.42(m,4H),1.24(dd,J＝10.3,4.9Hz,2H).
HR-MS(m/z)(ESI):calcd for C25H33NO8S,[M+H]+:508.20；found:508.2035.
(二)、目标化合物的制备
实施例1.化合物16的制备
将化合物13(250.0mg,0.51mmol)溶解于DMF(30mL)中，室温下依次加入TBTU(245.6mg,0.76mmol)、Et3N(106.4μL,0.765mmol)和邻苯二胺(108.0mg,1.01mmol)，在氮气保护下，反应混合物在35℃搅拌2h。在反应完成后，用DCM(300mL)萃取溶液，有机相用饱和食盐水溶液(100mL)洗涤三次，再用无水硫酸钠干燥，减压蒸馏，所得固体以DCM:MeOH(60:1-30:1)为洗脱剂，经硅胶层析法分离纯化，得淡黄色固体，产率36.2％.
1H NMR(600MHz,DMSO)δ9.20(s,1H),9.19(s,1H),8.02(s,1H),7.60(d,J＝15.6Hz,1H),7.15(dd,J＝7.7,0.9Hz,1H),7.12(d,J＝15.6Hz,1H),7.06–7.03(m,1H), 7.01(d,J＝8.4Hz,1H),6.89(td,J＝8.0,1.4Hz,1H),6.71(dd,J＝8.0,1.2Hz,1H),6.53(td,J＝7.7,1.2Hz,1H),6.29(s,2H),4.98(s,2H),4.35(s,2H),3.85(s,6H),3.84(s,3H),3.82(s,3H),2.73(t,J＝6.9Hz,2H),2.63(t,J＝7.0Hz,2H).13C NMR(151MHz,DMSO)δ171.12,170.91,164.11,161.43(C×2),149.88,142.49,133.38,127.72,127.45,126.31,126.00,124.78,124.01,123.84,121.10,116.56,116.15,111.26,103.05,91.40(C×2),60.34,56.53(C×2),56.22,56.09,32.01,31.36.
HR-MS(m/z)(ESI):calcd for C29H33N3O8S,[M+H]+:584.20；found:584.2095.
实施例2.化合物17的制备
按照上述化合物16的合成方法，使用化合物14代替化合物13反应，得到淡黄色固体，产率38.4％.
1H NMR(600MHz,DMSO)δ9.13(s,1H),9.12(s,1H),8.03(s,1H),7.60(d,J＝15.6Hz,1H),7.19-7.17(m,1H),7.13(d,J＝15.6Hz,1H),7.05(dd,J＝8.4,1.2Hz,1H),7.01(d,J＝8.5Hz,1H),6.91–6.88(m,1H),6.72(dd,J＝8.0,1.2Hz,1H),6.55(td,J＝7.8,1.2Hz,1H),6.29(s,2H),4.91(s,2H),4.35(s,2H),3.86(s,6H),3.84(s,3H),3.82(s,3H),2.45(t,J＝7.2Hz,2H),2.38(t,J＝7.4Hz,2H),1.88(dd,J＝14.6,7.3Hz,2H).13C NMR(151MHz,DMSO)δ171.45,171.26,164.12,161.43(C×2),150.00,142.32,133.41,127.61,127.70,126.20,125.87,124.99,124.03,124.02,121.08,116.65,116.35,111.26,103.05,91.41(C×2),60.33,56.53(C×2),56.22,56.08,35.91,35.52,21.84.
HR-MS(m/z)(ESI):calcd for C30H35N3O8S,[M+H]+:598.20；found:598.2320.
实施例3.化合物18的制备
按照上述化合物16的合成方法，使用化合物15代替化合物13反应，得到淡黄色固体，产率37.6％.
1H NMR(600MHz,DMSO)δ9.14(s,1H),9.07(s,1H),8.01(s,1H),7.60(d,J＝15.6Hz,1H),7.16(dd,J＝7.8,0.9Hz,1H),7.13(d,J＝15.6Hz,1H),7.05(d,J＝8.2Hz,1H),7.01(d,J＝8.5Hz,1H),6.91–6.88(m,1H),6.73(dd,J＝7.9,1.0Hz,1H),6.57–6.53(m,1H),6.29(s,2H),4.92(s,2H),4.35(s,2H),3.85(s,6H),3.84(s,3H),3.82(s,3H),2.42(s,2H),2.34(d,J＝6.0Hz,2H),1.63(s,4H).13C NMR(151MHz,DMSO)δ171.67,171.52,164.11,161.42(C×2),150.02,142.21,133.39,127.69,127.52,126.19,125.78,125.02,124.10,124.02,121.09,116.77,116.44,111.25,103.05,91.40(C×2),60.31,56.52(C×2),56.21,56.08,36.36,36.12,25.52.25.43
HR-MS(m/z)(ESI):calcd for C31H37N3O8S,[M+H]+:612.20；found:612.2515.
实施例4.化合物19的制备
将化合物13(208.0mg,0.42mmol)溶解于DMF(30mL)中，室温下依次加入TBTU(175.3mg,0.55mmol)、Et3N(350.6μL,2.52mmol)和NH2OH·HCl(116.7mg,1.68mmol)，在氮气保护下，反应混合物在35℃搅拌2h，通过TLC监测反应进程。在反应完成后，用DCM(300mL)萃取溶液，有机相用饱和食盐水溶液(100mL)洗涤三次，再用无水硫酸钠干燥，减压蒸馏，得到的固体以DCM:MeOH(50:1-20:1)为洗脱剂，经硅胶层析法进一步分离纯化，得黄色固体。产率60.9％.
1H NMR(600MHz,DMSO)δ10.43(s,1H),9.17(s,1H),8.74(s,1H),8.03(s,1H),7.59(d,J＝15.6Hz,1H),7.11(d,J＝15.6Hz,1H),7.01(t,J＝7.5Hz,2H),6.29(s,2H),4.34(s,2H),3.85(s,6H),3.84(s,3H),3.82(s,3H),2.63(t,J＝7.1Hz,2H),2.26(t,J＝7.1Hz,2H).13C NMR(151MHz,DMSO)δ170.77,168.91,164.11,161.42(C×2),149.77,133.38,127.73,127.40,124.62,123.99,121.07,111.22,103.03,91.40(C×2),60.35,56.53(C×2),56.22,56.08,31.82,28.01.
HR-MS(m/z)(ESI):calcd for C23H28N2O9S,[M+H]+:509.16；found:509.1625.
实施例5.化合物20的制备
按照上述化合物19的合成方法，使用化合物14代替化合物13反应，得到黄色固体，产率62.3％。
1H NMR(600MHz,DMSO)δ10.40(s,1H),9.08(s,1H),8.71(d,J＝1.1Hz,1H),8.00(s,1H),7.59(d,J＝15.6Hz,1H),7.12(d,J＝15.6Hz,1H),7.04(dd,J＝8.5,1.1Hz, 1H),7.01(d,J＝8.5Hz,1H),6.29(s,2H),4.35(s,2H),3.85(s,6H),3.84(s,3H),3.82(s,3H),2.37(t,J＝7.3Hz,2H),2.00(t,J＝7.4Hz,2H),1.79–1.76(m,2H).13C NMR(151MHz,DMSO)δ171.30,169.24,164.12,161.43(C×2),150.00,133.39,127.90–127.69,127.60,124.98,124.03,121.07,111.26,103.04,91.41(C×2),60.30,56.53(C×2),56.23,56.09,35.86,32.15,21.83.
HR-MS(m/z)(ESI):calcd for C24H30N2O9S,[M+H]+:523.16；found:523.1737
实施例6.化合物21的制备
按照上述化合物19的合成方法，使用化合物15代替化合物13反应，得到黄色固体，产率63.6％.
1H NMR(600MHz,DMSO)δ10.38(s,1H),9.05(s,1H),8.70(s,1H),7.99(s,1H),7.59(d,J＝15.6Hz,1H),7.12(d,J＝15.6Hz,1H),7.02(dd,J＝19.4,8.3Hz,2H),6.29(s,2H),4.34(s,2H),3.85(s,6H),3.84(s,3H),3.82(s,3H),2.37(s,2H),1.97(s,2H),1.52(s,4H).13C NMR(151MHz,DMSO)δ171.63,169.46,164.12,161.42(C×2),150.01,133.39,127.60,125.00,124.01,121.08,111.25,103.04,91.40(C×2),60.30,56.53(C×2),56.16,36.26,32.64,25.35.
HR-MS(m/z)(ESI):calcd for C25H32N2O9S,[M+H]+:537.16；found:537.1925.
实施例7.化合物31的制备
将化合物28(225.6mg,0.5mmol)溶解于DMF(30mL)中，室温下依次加入HATU(247.1mg,0.65mmol)、Et3N(90.3μL,0.65mmol)和邻苯二胺(162.15mg,1.5mmol)，在氮气保护下，反应混合溶液于35℃下搅拌2h，通过TLC监测反应进程。在反应完成后，用DCM(300mL)萃取溶液，有机相用饱和食盐水溶液(100mL)洗涤三次，再用无水硫酸钠干燥，减压蒸馏，所得固体以DCM:MeOH(100:1-80:1)为洗脱剂，经硅胶层析法进一步分离纯化，得淡黄色固体。产率37.0％.
1H NMR(600MHz,DMSO)δ9.18(s,1H),7.60(d,J＝15.7Hz,1H),7.18(dd,J＝7.8,1.2Hz,1H),7.11(d,J＝15.7Hz,1H),6.92–6.89(m,1H),6.83(d,J＝8.2Hz,1H),6.72(dd,J＝8.0,1.2Hz,1H),6.61(dd,J＝8.1,1.8Hz,1H),6.54(dd,J＝7.5,1.2Hz,1H),6.52(d,J＝1.9Hz,1H),6.29(s,2H),5.33(s,1H),4.87(s,2H),4.29(s,2H),3.86(s,2H),3.85(s,6H),3.84(s,3H),3.82(s,3H).13C NMR(151MHz,DMSO)δ169.00,164.08,161.40(C×2),147.10,142.66,137.68,133.22,126.56,126.18,124.15,119.90,116.61,116.18,112.72,109.95,91.44(C×2),60.93,56.52(C×2),56.08,55.95,47.03.
HR-MS(m/z)(ESI):calcd for C27H31N3O7S,[M+H]+:542.20；found:542.2022
实施例8.化合物32的制备
按照上述化合物31的合成方法，使用化合物29代替化合物28反应，得到淡黄色固体，产率38.4％.
1H NMR(600MHz,DMSO)δ9.19(s,1H),7.59(d,J＝15.7Hz,1H),7.14(dd,J＝15.8,8.2Hz,2H),6.92–6.89(m,1H),6.78(d,J＝8.2Hz,1H),6.72(d,J＝7.9Hz,1H),6.61(d,J＝1.5Hz,1H),6.58–6.53(m,2H),6.29(s,2H),4.94(d,J＝40.8Hz,3H),4.30(s,2H),3.85(s,6H),3.83(s,3H),3.77(s,3H),3.29(t,J＝6.4Hz,2H),2.62(t,J＝6.7Hz,2H).13C NMR(151MHz,DMSO)δ170.46,164.05,161.38(C×2),147.02,142.46,138.00,133.14,126.39,126.00,124.12,123.66,121.90,119.27,116.60,116.26,112.62,109.82,103.04,91.38(C×2),60.90,56.50(C×2),56.06,55.85,39.97,35.67.
HR-MS(m/z)(ESI):calcd for C28H33N3O7S,[M+H]+:556.22；found:556.2161.
实施例9.化合物33的制备
按照上述化合物31的合成方法，使用化合物30代替化合物28反应，得到淡黄色固体，产率39.3％.
1H NMR(600MHz,DMSO)δ9.08(s,1H),7.55(d,J＝15.7Hz,1H),7.16(dd,J＝7.8,1.1Hz,1H),7.12(d,J＝15.7Hz,1H),6.89(t,J＝7.6Hz,1H),6.75(d,J＝8.1Hz,1H),6.72(d,J＝9.1Hz,1H),6.55–6.52(m,2H),6.50(d,J＝1.6Hz,1H),6.29(s,2H),4.79(d,J＝76.4Hz,3H),4.28(s,2H),3.84(s,6H),3.84(s,3H),3.76(s,3H),2.95(t,J＝7.0Hz,2H),2.30(t,J＝7.4Hz,2H),1.58–1.53(m,4H),1.34–1.30(m,2H).13C NMR(151MHz,DMSO)δ171.57,164.05,161.39(C×2),146.79,142.29,138.24, 133.19,126.15,125.72,124.14,124.09,121.97,118.76,116.69,116.39,112.23,109.74,103.10,91.40(C×2),60.97,56.49(C×2),56.07,55.80,43.08,36.26,28.80,26.83,25.59.
HR-MS(m/z)(ESI):calcd for C31H39N3O7S,[M+H]+:598.26；found:598.2642.
实施例10.化合物34的制备
将化合物28(189.6mg,0.42mmol)溶解于DCM(30mL)中，室温下依次加入TBTU(175.3mg,0.55mmol)、Et3N(350.6μL,2.52mmol)和NH2OH·HCl(116.7mg,1.68mmol)，在氮气保护下，反应混合物在35℃搅拌2h，通过TLC监测反应进程。在反应完成后，用DCM(300mL)萃取溶液，有机相用饱和食盐水溶液(100mL)洗涤三次，再用无水硫酸钠干燥，减压蒸馏，所得固体以DCM:MeOH(60:1-20:1)为洗脱剂，经硅胶层析法进一步分离纯化，得黄色固体。产率52.6％。
1H NMR(600MHz,DMSO)δ10.63(s,1H),8.90(s,1H),7.60(s,1H),7.10(d,J＝15.6Hz,1H),6.81(d,J＝8.2Hz,1H),6.60(d,J＝8.0Hz,1H),6.46(d,J＝23.1Hz,1H),6.29(s,2H),5.09(s,1H),4.27(s,2H),3.85(s,6H),3.85(s,3H),3.80(s,3H),3.55(s,2H).13C NMR(151MHz,DMSO)δ166.93,164.08,161.41(C×2),147.10,137.63,133.20,124.10,121.75,119.93,112.76,109.89,103.05,91.43(C×2),60.90,56.51(C×2),56.08,55.92,44.40.
HR-MS(m/z)(ESI):calcd for C21H26N2O8S,[M+H]+:467.14；found:467.1579.
实施例11.化合物35的制备
按照上述化合物31的合成方法，使用化合物29代替化合物28反应，得到淡黄色固体，产率51.2％。
1H NMR(600MHz,DMSO)δ10.49(s,1H),8.82(s,1H),7.58(d,J＝15.7Hz,1H),7.13(d,J＝15.7Hz,1H),6.78(d,J＝8.0Hz,1H),6.56(d,J＝9.2Hz,2H),6.30(s,2H),4.92(s,1H),4.30(s,2H),3.86(d,J＝3.0Hz,9H),3.77(s,3H),3.19(t,J＝6.6Hz,2H),2.26(t,J＝6.8Hz,2H).13C NMR(151MHz,DMSO)δ168.29,164.04,161.37(C×2),146.92,137.81,133.10,124.08,121.86,119.25,112.47,109.77,103.00,91.37(C×2),60.78,56.50(C×2),56.07,55.81,39.87,32.30.
HR-MS(m/z)(ESI):calcd for C22H28N2O8S,[M+H]+:481.16；found:481.1663.
实施例12.化合物36的制备
按照上述化合物31的合成方法，使用化合物30代替化合物28反应，得到淡黄色固体，产率50.2％。
1H NMR(600MHz,DMSO)δ10.36(s,1H),8.70(s,1H),7.55(d,J＝15.7Hz,1H),7.12(d,J＝15.7Hz,1H),6.75(d,J＝8.2Hz,1H),6.52(dd,J＝8.1,1.7Hz,1H),6.48(d,J＝1.7Hz,1H),6.29(s,2H),4.72(s,1H),4.28(s,2H),3.85(s,9H),3.76(s,3H),2.92(dd,J＝12.7,6.6Hz,2H),1.93(t,J＝7.4Hz,2H),1.47(ddt,J＝22.9,15.2,7.4Hz,4H),1.24–1.20(m,2H).13C NMR(151MHz,DMSO)δ169.53,164.05,161.38(C×2),146.75,138.20,133.16,124.09,121.94,118.74,112.17,109.69,103.04,91.36(C×2),60.90,56.48(C×2),56.08,55.77,43.05,32.76,28.63,26.76,25.42.
HR-MS(m/z)(ESI):calcd for C25H34N2O8S,[M+H]+:523.21；found:523.2129.
(三)、化合物体外细胞毒活性测试
实验方法：取对数生长期的细胞计数，接种于96孔培养板内，每孔约8000-10000个细胞。培养过夜，待细胞贴壁后进行给药，分别设给药组和对照组。待测的目标化合物用DMSO溶液配制成贮液，临用前用细胞培养基稀释成一系列浓度，其中DMSO的终浓度不超过4‰(下面实验类同)。每个浓度设3个复孔。加药后培养72h，加20μL浓度为5mg/mL的MTT，37℃孵育4h，弃去上清，加入150μL的DMSO溶解。用酶标仪在490纳米波长下测定每孔的OD值，并计算抑制率，做浓度-抑制率曲线计算IC50值。
实验例1.
测试了目标化合物对非小细胞肺癌细胞A549和H1975、胃癌细胞SGC-7901、肝癌细胞HepG2、乳腺癌细胞MCF-7和表皮癌细胞A431的抗增殖活性以及它们对人正常肝细胞LO2和脐静脉内皮细胞HUVEC的毒性，母体化合物9和HDAC抑制剂SAHA作为阳性对照。观察化合物在不同浓度下对肿瘤细胞生长的抑制情况，计算抑制率及其IC50值来评价药物的细胞毒活性，结果见表2。
表2.化合物的体外抗癌活性及对正常细胞的毒性
Figure PCTCN2021116466-appb-000009
实验例2.
测试了目标化合物19和34对胰腺癌细胞PANC-1、结肠癌细胞HT29、慢性粒细胞白血病癌细胞K562和人髓性单核细胞白血病细胞MV4-11的抗增殖活性，母体化合物9和HDAC抑制剂SAHA作为阳性对照。观察化合物在不同浓度下对肿瘤细胞生长的抑制情况，计算抑制率及其IC 50值来评价药物的细胞毒活性，结果见表3。
表3.化合物19和34对一些癌细胞的IC 50值
Figure PCTCN2021116466-appb-000010
(四)、化合物对HDAC的抑制活性检测
实验方法：根据人组蛋白脱乙酰基酶HDAC试剂盒说明书(上海抚生实业有限公司生产)，应用双抗体夹心法测定样品中人组蛋白脱乙酰基酶(HDAC1、2、3、4、6、8)水平。分别设空白孔(空白对照孔不加样品及酶标试剂，其余各步操作相同)、标准孔、待测样品孔。将不同浓度的药物与HDAC亚型蛋白混合加于酶标板孔底部，用封板膜封板后置37℃温育30min。用洗涤液洗涤5次后，于每孔中加入酶标试剂50μL，空白孔除外。再封板后置37℃温育30min，洗涤5次。然后每孔先加入显色剂A 50μL，再加入显色剂B 50μL，轻轻震荡混匀，37℃避光显色10min。最后每孔加终止液50μL，终止反应。以空白孔调零，用酶标仪在450nm波长依序测量各孔的吸光度(OD值)。并计算抑制率，做浓度-抑制率曲线计算IC 50值。
实验例3.
测试了目标化合物19和34对六种HDAC亚型的抑制情况，即HDAC1、HDAC2、HDAC3、HDAC4、HDAC6、HDAC8。以HDAC抑制剂SAHA为阳性对照，观察化合物在不同浓度下对HDAC酶的抑制情况，计算抑制率及其IC 50值来评价化合物的酶活性，结果见表4。
表4.化合物对人组蛋白去乙酰化酶HDAC的抑制活性
Figure PCTCN2021116466-appb-000011
(五)、化合物对RAS和RAF蛋白作用的检测
实验方法：采用免疫共沉淀和免疫印迹检测的实验方法测试化合物对RAS和RAF蛋白的作用。取对数生长期的H1975细胞计数，接种于6孔培养板内，每孔约100000-1000000个细胞，培养过夜，待细胞贴壁后进行给药处理24h。消化细胞，转移至离心管中，加入预冷的细胞裂解液，置于4℃摇床平台上，温和振荡15min；然后在10,000rpm，4℃的条件下离心5min，取上清液转移至新的离心管中。此时将上清液分为两组，一组为IP组，在上清液中加入RAS抗体，4℃慢摇过夜。加入充分重悬的G蛋白琼脂糖，4℃慢摇4h。2500rpm离心5min，小心吸除上清，PBS洗涤沉淀5次。完成洗涤后，去除上清，加入1xSDS-PAGE电泳上样缓冲液重悬，混匀后，95℃水浴10min，作为样品蛋白,然后通过免疫印迹的方法来检测。另一组作为input组，直接在上清液中加入1xSDS-PAGE电泳上样缓冲液重悬，混匀后，95℃水浴10min，作为样品蛋白，然后再通过免疫印迹的实验方法来检测。
首先配制分离胶和浓缩胶，待胶成型后，吸取适量样品蛋白加入样品孔中，在样品旁的孔中加入预染的蛋白Marker，未添加样品上清的孔中，加入1x SDS上样缓冲液保持胶面平衡。打开电源，，电压开始设置为60V，开始电泳，当蛋白样品进入分离胶后，电压可提高到120V。电泳完成后，开始转PVDF膜，设置电流流1.1A，电压25V，时间30min进行半干转。转膜结束后，取出PVDF膜并作好标记，用TBST溶液洗涤3次，每次10min。接着将PVDF膜放入平皿中，加入封闭液，摇床振荡1.5-2h。封闭结束后，用TBST溶液洗涤。接着将膜放入含一抗的孵育盒中，4℃摇床振荡孵育过夜。第二天取出，室温振荡30min，吸弃一抗，TBST洗涤3次。二抗孵育，室温摇床振荡反应2h。二抗反应结束后用TBST洗涤。将EcL化学发光试剂盒中的A、B两种液体按l:l等体积混合，配置成工作液备用。将PVDF膜从TBST中取出，滴加适量工作液，使用G:BOX chemiXR5显色成像
实验例4.
测试了化合物19和34对RAS和RAF蛋白的作用，以化合物9和SAHA作为阳性对照。观察不同化合物在同等浓度下对RAS和RAF蛋白表达的影响，结果见图1。

Claims (9)

  1. 一种含有RAS/RAF蛋白干扰基团的HDAC抑制剂，其特征在于所述的一类HDAC抑制剂，是基于已知的以RAS/RAF为靶点的2,4,6-三甲氧基苯基-4-甲氧基-3-氨基苄基砜(9)为帽基基团，其结构如式1所示，
    Figure PCTCN2021116466-appb-100001
    通过连接基团在其结构引入苯甲酰胺或羟肟酸结构单元，得到结构如式2所示的化合物即HDAC抑制剂，分为以下具有代表性的I-A、I-B、I-C、I-D 4种化合物，
    Figure PCTCN2021116466-appb-100002
    式2中，n＝1-5。
  2. 一种如权利要求1所述的含有RAS/RAF蛋白干扰基团的HDAC抑制剂的制备方法，其特征在于，HDAC抑制剂I-A按照以下反应式3-1进行制备：
    Figure PCTCN2021116466-appb-100003
    其中，TBTU代表2-(1H-苯并三偶氮L-1-基)-1,1,3,3-四甲基脲四氟硼酸酯，Et 3N代表三乙胺，DMF代表N,N-二甲基甲酰胺。
  3. 根据权利要求2所述的含有RAS/RAF蛋白干扰基团的HDAC抑制剂的制备方法，其特征在于，合成HDAC抑制剂I-A具体采用如下步骤：
    将化合物13、14或15与1.0-1.5当量TBTU溶于无水DMF中，在室温下搅拌5-10min，加入1.0-1.5当量的Et 3N，再加入1.0-2.0当量的邻苯二胺，在氮气保护下，反应液于25-35℃下搅拌2-4h，然后减压除去溶剂，浓缩液经硅胶柱层析分离，洗脱液为DCM与CH 3OH混合溶剂，分别对应得到化合物16、17或18淡黄色固体产物。
  4. 一种如权利要求1所述的含有RAS/RAF蛋白干扰基团的HDAC抑制剂的制备方法，其特征在于，HDAC抑制剂I-B按照以下反应式3-2进行制备：
    Figure PCTCN2021116466-appb-100004
    其中，TBTU代表2-(1H-苯并三偶氮L-1-基)-1,1,3,3-四甲基脲四氟硼酸酯，Et 3N代表三乙胺，DMF代表N,N-二甲基甲酰胺。
  5. 根据权利要求4所述的含有RAS/RAF蛋白干扰基团的HDAC抑制剂的制备方法，其特征在于，合成HDAC抑制剂I-B具体采用如下步骤：
    将化合物13、14或15与1.0-1.5当量TBTU溶于无水DMF中，在室温下搅拌5-10min，加入1.0-1.5当量的Et 3N，再加入1.0-2.0当量的盐酸羟胺，在氮气保护下，反应液于25-35℃下搅拌2-4h，然后减压除去溶剂，浓缩液经硅胶柱层析分离，洗脱液为DCM与CH 3OH混合溶剂，分别对应得到化合物19、20或21淡黄色固体产物。
  6. 一种如权利要求1所述的含有RAS/RAF蛋白干扰基团的HDAC抑制剂的制备方法，其特征在于，HDAC抑制剂I-C按照以下反应式3-3进行制备：
    Figure PCTCN2021116466-appb-100005
    其中，TBTU代表2-(1H-苯并三偶氮L-1-基)-1,1,3,3-四甲基脲四氟硼酸酯，Et 3N代表三乙胺，DCM代表二氯甲烷。
  7. 一种如权利要求6所述的含有RAS/RAF蛋白干扰基团的HDAC抑制剂的制备方法，其特征在于，合成HDAC抑制剂I-C具体采用如下步骤：
    将化合物28、29或30与1.0-1.5当量HATU溶于无水DCM中，在室温下搅拌5-10min，加入1.0-1.5当量的Et 3N，再加入1.0-2.0当量的邻苯二胺，在氮气保护下，反应液于25-35℃下搅拌2-4h，然后减压除去溶剂，浓缩液经硅胶柱层析分离，洗脱液为DCM与CH 3OH混合溶剂，得到31、32或33淡黄色固体产物。
  8. 一种如权利要求1所述的含有RAS/RAF蛋白干扰基团的HDAC抑制剂的制备方法，其特征在于，HDAC抑制剂I-D按照以下反应式进行制备：
    Figure PCTCN2021116466-appb-100006
    其中，TBTU代表缩合剂2-(1H-苯并三偶氮L-1-基)-1,1,3,3-四甲基脲四氟硼酸酯，Et 3N代表三乙胺，DCM代表二氯甲烷。
  9. 根据权利要求8所述的含有RAS/RAF蛋白干扰基团的HDAC抑制剂的制备方法，其特征在于，合成HDAC抑制剂I-D具体采用如下步骤：
    将化合物28、29或30与1.0-1.5当量TBTU溶于无水DCM中，在室温下搅拌5-10min，加入1.0-1.5当量的Et 3N，再加入1.0-2.0当量的盐酸羟胺，在氮气保护下，反应液于25-35℃下搅拌2-4h，然后减压除去溶剂，浓缩液经硅胶柱层析分离，洗脱液为DCM与CH 3OH混合溶剂，得到34、35或36淡黄色固体产物。
PCT/CN2021/116466 2020-11-26 2021-09-03 含有ras/raf蛋白干扰基团的hdac抑制剂及其制备方法 WO2022110958A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202011345547.7A CN114539110B (zh) 2020-11-26 2020-11-26 含有ras/raf蛋白干扰基团的hdac抑制剂及其制备方法
CN202011345547.7 2020-11-26

Publications (1)

Publication Number Publication Date
WO2022110958A1 true WO2022110958A1 (zh) 2022-06-02

Family

ID=81659448

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/116466 WO2022110958A1 (zh) 2020-11-26 2021-09-03 含有ras/raf蛋白干扰基团的hdac抑制剂及其制备方法

Country Status (2)

Country Link
CN (1) CN114539110B (zh)
WO (1) WO2022110958A1 (zh)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002026703A1 (en) * 2000-09-29 2002-04-04 Prolifix Limited Carbamic acid compounds comprising an ether linkage as hdac inhibitors
WO2003072062A2 (en) * 2002-02-28 2003-09-04 Temple University-Of The Commonwealth System Of Higher Education Amino-substituted (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders
WO2006010152A2 (en) * 2004-07-19 2006-01-26 Onconova Therapeutics, Inc. Formulations for parenteral administration of (e)-2,6-dialkoxystryryl 4-substituted benzylsulfones
WO2006117548A1 (en) * 2005-05-05 2006-11-09 Chroma Therapeutics Ltd Hydroxamic acid dervicatives as inhibitors of hdac enzymatic activity
WO2008033475A2 (en) * 2006-09-15 2008-03-20 Onconova Therapeutics, Inc. Activated cytotoxic compounds for attachment to targeting molecules for the treatment of mammalian disease conditions
WO2008088803A2 (en) * 2007-01-16 2008-07-24 Onconova Therapeutics, Inc. Formulations for parenteral administration of (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones
WO2010075542A1 (en) * 2008-12-23 2010-07-01 Curis, Inc. Cdk inhibitors

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002026703A1 (en) * 2000-09-29 2002-04-04 Prolifix Limited Carbamic acid compounds comprising an ether linkage as hdac inhibitors
WO2003072062A2 (en) * 2002-02-28 2003-09-04 Temple University-Of The Commonwealth System Of Higher Education Amino-substituted (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders
WO2006010152A2 (en) * 2004-07-19 2006-01-26 Onconova Therapeutics, Inc. Formulations for parenteral administration of (e)-2,6-dialkoxystryryl 4-substituted benzylsulfones
WO2006117548A1 (en) * 2005-05-05 2006-11-09 Chroma Therapeutics Ltd Hydroxamic acid dervicatives as inhibitors of hdac enzymatic activity
WO2008033475A2 (en) * 2006-09-15 2008-03-20 Onconova Therapeutics, Inc. Activated cytotoxic compounds for attachment to targeting molecules for the treatment of mammalian disease conditions
WO2008088803A2 (en) * 2007-01-16 2008-07-24 Onconova Therapeutics, Inc. Formulations for parenteral administration of (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones
WO2010075542A1 (en) * 2008-12-23 2010-07-01 Curis, Inc. Cdk inhibitors

Also Published As

Publication number Publication date
CN114539110A (zh) 2022-05-27
CN114539110B (zh) 2023-02-14

Similar Documents

Publication Publication Date Title
CA3029911C (en) Antimetastatic 2h-selenopheno[3,2-h]chromenes, synthesis thereof, and methods of using same agents
Ge et al. Design and synthesis of parthenolide-SAHA hybrids for intervention of drug-resistant acute myeloid leukemia
CN107033043B (zh) N-取代苯磺酰基-取代苯甲酰胺类化合物及其制备药物的用途
CN113264859B (zh) 萘磺胺异硫氰酸酯类双功能小分子及其制备方法和应用
CN113004251B (zh) 含2-硝基咪唑的喹唑啉类衍生物及其应用
Li et al. Synthesis, biological evaluation and molecular docking studies of 3-(1, 3-diphenyl-1H-pyrazol-4-yl)-N-phenylacrylamide derivatives as inhibitors of HDAC activity
Chen et al. Discovery of novel benzimidazole derivatives as potent p300 bromodomain inhibitors with anti-proliferative activity in multiple cancer cells
US20220401419A1 (en) Hydrogen peroxide-responsive keap1-nrf2 ppi inhibitor prodrug, and preparation method therefor
WO2022110958A1 (zh) 含有ras/raf蛋白干扰基团的hdac抑制剂及其制备方法
JP6487333B2 (ja) 抗生物質の活性を増強する活性を有するスピロイソオキサゾリン化合物
EP3042913B1 (en) Cyclic peptide compound, and preparation method, pharmaceutical composition and use thereof
CN107417592A (zh) 一种1h‑吲哚‑2‑氧代乙酰胺衍生物及其制备方法与应用
CN115010658B (zh) 一种化合物及其制备方法与应用
CN113527195B (zh) 一类5-芳基烟酰胺类lsd1/hdac双靶点抑制剂、其制备方法及应用
Liu et al. Synthesis and biological study of class I selective HDAC inhibitors with NO releasing activity
TW201922690A (zh) 環－amp反應元素結合蛋白的抑制劑
RU2264393C2 (ru) Конденсированные производные тиоколхицина и баккатина в качестве противоопухолевых агентов
CN106957298B (zh) 一种硫辛酸苯酚酯衍生物及其制备方法和应用
EP1652849A1 (en) Novel hydrophilic analogs of 4,8-dihydrobenzodithiophene-4,8-diones as anticancer agents
Xu et al. Structure-activity relationship studies on O-alkylamino-tethered salicylamide derivatives with various amino acid linkers as potent anticancer agents
CN109761932A (zh) 吩噻嗪类化合物及其应用
CN116284202B (zh) 白桦脂酸的PROTACs化合物及其制备方法和应用
CN114907437B (zh) 具有抗肿瘤活性的雄诺龙衍生物及其制备方法与应用
WO2022227873A1 (zh) 具有kga抑制活性的化合物及其合成方法和应用
Karadkhelkar Chemical Synthesis and Evaluation of Azotochelin Analogs as Anticancer Agents and Their Ability to Reverse Anticancer Drug Resistance

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21896462

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21896462

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 21896462

Country of ref document: EP

Kind code of ref document: A1

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 17/01/2024)